Recruitment of patients has begun for the second phase of Canopus’ Hepatitis C patient study at the Brooke Army Medical Center in Texas. This new wave of patients will evaluate the combination of Canopus’ Hepatitis C drug candidate, CB5300 with the well known statin, fluvastatin.
CB5300 alone has already proven to be non-toxic with dose-dependent antiviral activity in patients. Canopus expects the combination with fluvastatin to further enhance the efficacy of its Hepatitis C drug candidate CB5300.